{"id":"NCT00356408","sponsor":"UCB Pharma","briefTitle":"Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease","officialTitle":"An Open-label, Multi-center Trial to Examine the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease Previously Enrolled in C87059 (COSPAR I, NCT00349752).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-01","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2006-07-26","resultsPosted":"2011-05-25","lastUpdate":"2018-08-09"},"enrollment":106,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Crohn's Disease"],"interventions":[{"type":"BIOLOGICAL","name":"Certolizumab pegol","otherNames":["CDP870","CZP","Cimzia"]}],"arms":[{"label":"CDP870 400 mg","type":"EXPERIMENTAL"}],"summary":"This is an open-label extension study designed to measure the safety, efficacy, and corticosteroid-sparing effect of certolizumab pegol (CDP870) in patients with moderate to severe Crohn's disease previously enrolled in C87059 (COSPAR I, NCT00349752).","primaryOutcome":{"measure":"Occurrence of at Least One Treatment-emergent Adverse Event During This Study (Maximum 122 Weeks)","timeFrame":"During this study (maximum 122 weeks)","effectByArm":[{"arm":"Placebo/Completer","deltaMin":12,"sd":null},{"arm":"CDP870/Completer","deltaMin":15,"sd":null},{"arm":"Placebo/Non-completer","deltaMin":32,"sd":null},{"arm":"CDP870/Non-completer","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":3},"locations":{"siteCount":63,"countries":["United States","Canada","Germany"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":14},"commonTop":["Crohn's Disease","Arthralgia","Upper Respiratory Tract Infection","Nasopharyngitis","Nausea"]}}